Dr. Kaeberlein's Optispan Podcast Series - Rapamycin and More

Key Takeaways

• Grapefruit juice raises rapamycin exposure 3‑4×.
• Berberine modestly increases rapamycin exposure 1.5‑2.5×.
• Grapefruit effect persists 24‑72 hrs after ingestion.
• Berberine inhibition varies due to low bioavailability.
• 6 mg rapamycin + juice equals ~18‑21 mg alone.

Pulse Analysis

Rapamycin’s clinical appeal—from organ‑transplant immunosuppression to experimental longevity regimens—hinges on precise dosing. The drug is metabolized primarily by the hepatic enzyme CYP3A4 and the intestinal transporter P‑glycoprotein, which together limit its oral bioavailability to roughly 15 %. Any co‑administered substance that alters these pathways can dramatically shift systemic exposure, making drug‑interaction awareness essential for clinicians and self‑medicating patients alike.

Grapefruit juice stands out as a potent, irreversible inhibitor of intestinal CYP3A4 and P‑gp. Studies in transplant cohorts demonstrate a 3‑4‑fold increase in rapamycin AUC and a 2.5‑3.5‑fold rise in Cmax, effectively converting a 6 mg dose into the exposure of 18‑21 mg of rapamycin alone. Because the enzyme destruction persists for 24‑72 hours, the effect is predictable and can be leveraged to stretch dosing schedules, offering a cost‑saving strategy without compromising therapeutic levels—provided patients monitor for signs of over‑immunosuppression.

Berberine, a plant‑derived alkaloid, offers a milder, reversible CYP3A4 inhibition alongside modest P‑gp blockade. Its impact on rapamycin exposure is estimated at 1.5‑2.5× AUC, with a shorter duration tied to berberine’s ~3‑5‑hour half‑life and low (~5 %) oral bioavailability. This variability introduces uncertainty, especially across diverse gut microbiomes that influence berberine conversion. Practitioners considering berberine must weigh the modest potency against the risk of inconsistent rapamycin levels, potentially adjusting doses more conservatively than with grapefruit juice.